N-PhenoGENICS: Neurocognitive-Phenome, Genome, Epigenome and Nutriome In Childhood Leukemia Survivors
Childhood Leukemia Survivors
Conditions: official terms
Conditions: Keywords
Childhood leukemia survivors, Acute lymphoblastic leukemia, Leukemia, Late effects, Folate, Blood folate, Neurotoxicity, Methotrexate, Pharmacogenetics, Cognitive, Cognitive late effects, N-PhenoGENICS
Study Type
Study Phase
Study Design
Observational Model: Case Control, Time Perspective: Prospective
Overall Status
To find possible therapeutic targets to help prevent long-term brain and behavioural side effects in survivors of childhood leukemia that may have been caused by chemotherapy (Treatment-Related late Adverse Neuro-Cognitive Effects: TRANCE). The study hypothesis is that genetic variations of the elements in the folate-related cycles and methotrexate disposition networks are associated with the TRANCE phenotype of childhood leukemia survivors.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: 20 Years
Minimum Age: 8 Years
Gender: Both
Criteria: Inclusion Criteria:

- Past diagnosis of acute lymphoblastic leukemia

- 8 years : 0 months - 20 years : 11 months old at the time of their study visit

- At least 2 years : 0 months from the last treatment for acute lymphoblastic leukemia at the time of their study visit

- Continuous complete remission and undergone no bone marrow transplantation

- Fluent in English (a subject and one parent) for test completion

- Signed informed consent

Exclusion Criteria:

- Inability to complete the phenotyping tests

- Down Syndrome diagnosis
The Hospital for Sick Children
Toronto, Ontario, Canada
Status: Recruiting
Contact: Vitti - 416-813-8285 - michelle.vitti@sickkids.ca
Start Date
July 2013
The Hospital for Sick Children
The Hospital for Sick Children
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page